Traws Pharma submits Phase 2 protocols for bird flu and COVID drugs; requests FDA meeting

Traws Pharma, Inc.

Submitted HREC Phase 2 protocol for tivoxavir marboxil (TXM) to treat H5N1 bird flu and seasonal influenza.
Submitted Type D FDA meeting request to discuss accelerated approval for TXM under the Animal Rule.
Submitted HREC Phase 2 protocol for ratutrelvir in acute COVID, including PAXLOVID-ineligible patients, with rebound and Long COVID assessments.
Cash and equivalents of $15.9M as of March 31, 2025, expected to fund operations into Q1 2026.
Continuing discussions with BARDA regarding strategic stockpile inclusion for TXM.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.